Federal health researchers have halted testing a combination of Eli Lilly & Co.’s Covid-19 antibody drug and remdesivir in hospitalized Covid-19 patients, after an independent committee found a lack of a benefit.
The National Institute of Allergy and Infectious Diseases, which is funding the study, said Monday it was planning to test other experimental drugs as Covid-19 treatments in the study. Lilly said it would continue testing its antibody drug in other studies, in patients earlier in the course of their disease, and in…
